Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Hangzhou Alltest Biotech Co., Ltd. (688606.SS)
Hangzhou, CN
Hangzhou Alltest Biotech Co., Ltd. operates internationally, specializing in the entire process of in vitro diagnostic reagents, from their initial research and development to manufacturing and market distribution. The company supplies a wide array of rapid diagnostic solutions, encompassing crucial health sectors like women's health, infectious disease detection, drug screening, cancer diagnostics, and cardiovascular conditions, among other distinct product series. This enterprise is headquartered in Hangzhou, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.34% | -4.76% | -12.15% | -31.24% | -28.92% | -25.73% | -26.49% | -27.95% | -55.16% | -59.63% | -59.63% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Medical - Instruments & Supplies: +7.9%+4.5% Q1'26: -6.3% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%-27.2% Q1'26: -68.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+17.9% Q1'26: -28.1% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+27.5% ★ Q1'26: +11.2% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+14.0% ★ Q1'26: +4.7% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%+0.2% Q1'26: +1.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.03× ★ Q1'26: 0.08× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|
| Revenue |
866.58M
est: 870.00M (-0.4%)
|
905.34M
est: 1.13B (-19.9%)
|
1.49B
1.49B – 1.49B
+31.9% YoY
|
1.98B
1.98B – 1.98B
+32.9% YoY
|
| EBITDA |
375.44M
est: 335.78M (+11.8%)
|
274.95M
est: 436.12M (-37.0%)
|
575.45M
575.45M – 575.45M
+31.9% YoY
|
764.57M
764.57M – 764.57M
+32.9% YoY
|
| EBIT |
349.60M
est: 318.74M (+9.7%)
|
249.11M
est: 414.00M (-39.8%)
|
546.26M
546.26M – 546.26M
+31.9% YoY
|
725.78M
725.78M – 725.78M
+32.9% YoY
|
| Net Income |
302.47M
est: 304.00M (-0.5%)
|
220.19M
est: 361.15M (-39.0%)
|
489.74M
489.74M – 489.74M
+35.6% YoY
|
634.20M
634.20M – 634.20M
+29.5% YoY
|
| SGA |
120.23M
est: 89.57M (+34.2%)
|
76.58M
est: 116.34M (-34.2%)
|
153.51M
153.51M – 153.51M
+31.9% YoY
|
203.96M
203.96M – 203.96M
+32.9% YoY
|
| EPS |
3.82
est: 3.83 (-0.3%)
|
2.78
est: 4.55 (-38.9%)
|
6.17
6.17 – 6.17
+35.6% YoY
|
7.99
7.99 – 7.99
+29.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-25 | A | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-22 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-19 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-15 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 2/5 | 5/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 2/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Fei Gao | Chairman & GM | — | male |
| Weike Lu | Deputy GM & Director | — | male |
| Yanping Fu | Accounting Supervisor, Chief Financial Officer & Secretary of the Board of Directors | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688606.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
